{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:24:00Z","timestamp":1791721440451,"version":"4.3.4"},"reference-count":69,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCR"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been\ndemonstrated as a major risk factor in inducing coronary stent thrombosis due to its propensity to\ncreate a pro-thrombotic state. This review explores the mechanisms that may contribute to the increased\nthrombosis risk seen in COVID-19. Furthermore, we discuss the patient and haematological\nfactors that predispose to an increased risk of stent thrombosis, as well as the role of certain antiplatelet\nand anticoagulation therapies, including ticagrelor and enoxaparin, that may reduce the\nlikelihood and severity of in-stent thrombosis, in SARS-CoV-2 infection. To counter the proinflammatory\nand pro-thrombotic state shown in COVID-19, anti-thrombotic therapy in the future\nmay be optimised using point-of-care platelet inhibition testing and inflammation-modifying therapies.\nLarge-scale randomised trials with long-term follow-up are increasingly necessary to assess\nthe intersection of COVID-19 and stent optimisation as well as the reduction of stent thrombosis\nafter drug-eluting stent (DES) implantation.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573403x18666220512142019","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T06:46:09Z","timestamp":1652424369000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In-stent Thrombosis and COVID-19 Infection: Current Insights on the\nMechanistic Relationship"],"prefix":"10.2174","volume":"19","author":[{"given":"Ioannis","family":"Felekos","sequence":"first","affiliation":[{"name":"Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Medany","sequence":"additional","affiliation":[{"name":"Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Kandoole","sequence":"additional","affiliation":[{"name":"Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lonsdale","sequence":"additional","affiliation":[{"name":"Weston\nGeneral Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemina","family":"Doolub","sequence":"additional","affiliation":[{"name":"Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"WHO Coronavirus (COVID-19) dashboard. 2022. Available from: WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. World Health Organisation"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40265-020-01377-x","volume":"80","author":"Hajra A.","year":"2020","unstructured":"Hajra A.; Mathai S.V.; Ball S.; Management of thrombotic complications in COVID-19: an update. Drugs 2020,80(15),1553-1562","journal-title":"Drugs"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10557-020-07084-9","volume":"35","year":"2021","unstructured":"G\u0105secka A, Borovac JA, Guerreiro RA, et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther 2021,35(2),215-29","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jvscit.2020.06.012","volume":"6","author":"Levolger S.","year":"2020","unstructured":"Levolger S.; Bokkers R.P.H.; Wille J.; Kropman R.H.J.; de Vries J.P.M.; Arterial thrombotic complications in COVID-19 pa-tients. J Vasc Surg Cases Innov Tech 2020,6(3),454-459","journal-title":"J Vasc Surg Cases Innov Tech"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00277-020-04216-x","volume":"99","author":"Hanif A.","year":"2020","unstructured":"Hanif A.; Khan S.; Mantri N.; Thrombotic complications and anticoagulation in COVID-19 pneumonia: A New York City hospital experience. Ann Hematol 2020,99(10),2323-2328","journal-title":"Ann Hematol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","volume":"46","author":"Helms J.","year":"2020","unstructured":"Helms J.; Tacquard C.; Severac F.; High risk of throm-bosis in patients with severe SARS-CoV-2 infection: A multi-center prospective cohort study. Intensive Care Med 2020,46(6),1089-1098","journal-title":"Intensive Care Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jocs.14808","volume":"35","author":"Shafi A.M.A.","year":"2020","unstructured":"Shafi A.M.A.; Shaikh S.A.; Shirke M.M.; Iddawela S.; Harky A.; Cardiac manifestations in COVID-19 patients-A systematic review. J Card Surg 2020,35(8),1988-2008","journal-title":"J Card Surg"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.hrthm.2020.06.026","volume":"17","author":"Mitrani R.D.","year":"2020","unstructured":"Mitrani R.D.; Dabas N.; Goldberger J.J.; COVID-19 cardiac inju-ry: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm 2020,17(11),1984-1990","journal-title":"Heart Rhythm"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1161\/CIRCULATIONAHA.120.047349","volume":"141","author":"Hendren N.S.","year":"2020","unstructured":"Hendren N.S.; Drazner M.H.; Bozkurt B.; Cooper L.T.; Descrip-tion and proposed management of the acute COVID-19 cardi-ovascular syndrome. Circulation 2020,141(23),1903-1914","journal-title":"Circulation"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jaccas.2020.05.024","volume":"2","author":"Prieto-Lobato A.","year":"2020","unstructured":"Prieto-Lobato A.; Ramos-Mart&#xED;nez R.; Vallejo-Calcerrada N.; Corb&#xED;-Pascual M.; C&#xF3;rdoba-Soriano J.G.; A case series of stent thrombosis during the COVID-19 pandemic. JACC Case Rep 2020,2(9),1291-1296","journal-title":"JACC Case Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"Mauri L.","year":"2007","unstructured":"Mauri L.; Hsieh W.H.; Massaro J.M.; Ho K.K.; D\u2019Agostino R.; Cutlip D.E.; Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007,356(10),1020-1029","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/micc.12120","volume":"21","author":"Senchenkova E.Y.","year":"2014","unstructured":"Senchenkova E.Y.; Russell J.; Esmon C.T.; Granger D.N.; Roles of Coagulation and fibrinolysis in angiotensin II-enhanced microvascular thrombosis. Microcirculation 2014,21(5),401-407","journal-title":"Microcirculation"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/HYPERTENSIONAHA.110.158220","volume":"56","author":"Senchenkova E.Y.","year":"2010","unstructured":"Senchenkova E.Y.; Russell J.; Almeida-Paula L.D.; Harding J.W.; Granger D.N.; Angiotensin II-mediated microvascular throm-bosis. Hypertension 2010,56(6),1089-1095","journal-title":"Hypertension"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/ajh.25982","volume":"95","author":"Hanff T.C.","year":"2020","unstructured":"Hanff T.C.; Mohareb A.M.; Giri J.; Cohen J.B.; Chirinos J.A.; Thrombosis in COVID-19. Am J Hematol 2020,95(12),1578-1589","journal-title":"Am J Hematol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280","journal-title":"Cell"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","volume":"17","author":"Tai W.","year":"2020","unstructured":"Tai W.; He L.; Zhang X.; Characterization of the Receptor-Binding Domain (RBD) of 2019 novel coronavirus: implica-tion for development of RBD protein as a viral attachment in-hibitor and vaccine. Cell Mol Immunol 2020,17(6),613-620","journal-title":"Cell Mol Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1172\/JCI117809","volume":"95","author":"Vaughan D.E.","year":"1995","unstructured":"Vaughan D.E.; Lazos S.A.; Tong K.; Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995,95(3),995-1001","journal-title":"J Clin Invest"},{"key":"ref=18","first-page":"419","volume":"45","author":"Brown N.J.","year":"2000","unstructured":"Brown N.J.; Vaughan D.E.; Prothrombotic effects of angioten-sin. Adv Intern Med 2000,45,419-429","journal-title":"Adv Intern Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.thromres.2015.12.008","volume":"138","author":"Gromotowicz-Poplawska A.","year":"2016","unstructured":"Gromotowicz-Poplawska A.; Stankiewicz A.; Kramkowski K.; The acute prothrombotic effect of aldosterone in rats is partially mediated via angiotensin II receptor type 1. Thromb Res 2016,138,114-120","journal-title":"Thromb Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"64109394","DOI":"10.1016\/j.cellsig.2019.109394","author":"Sun T.","year":"2019","unstructured":"Sun T.; Ghosh A.K.; Eren M.; Miyata T.; Vaughan D.E.; PAI-1 contributes to homocysteine-induced cellular senescence. Cell Signal 2019,64109394","journal-title":"Cell Signal"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/jcm8050728","volume":"8","author":"Iba T.","year":"2019","unstructured":"Iba T.; Levy J.H.; Raj A.; Warkentin T.E.; Advance in the man-agement of sepsis-induced coagulopathy and disseminated in-travascular coagulation. J Clin Med 2019,8(5),728","journal-title":"J Clin Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"Tang N.","year":"2020","unstructured":"Tang N.; Li D.; Wang X.; Sun Z.; Abnormal coagulation parame-ters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020,18(4),844-847","journal-title":"J Thromb Haemost"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","volume":"191","author":"Lodigiani C.","year":"2020","unstructured":"Lodigiani C.; Iapichino G.; Carenzo L.; Venous and arteri-al thromboembolic complications in COVID-19 patients ad-mitted to an academic hospital in Milan, Italy. Thromb Res 2020,191,9-14","journal-title":"Thromb Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/CM9.0000000000000824","volume":"133","author":"Deng Y.","year":"2020","unstructured":"Deng Y.; Liu W.; Liu K.; Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: A retrospective study. Chin Med J 2020,133(11),1261-1267","journal-title":"Chin Med J"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P.","year":"2020","unstructured":"Zhou P.; Yang X.L.; Wang X.G.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-30","journal-title":"Nature"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","volume":"39","author":"Chousterman B.G.","year":"2017","unstructured":"Chousterman B.G.; Swirski F.K.; Weber G.F.;  Seminars in immunopathology 2017,39,517-28","journal-title":"Seminars in immunopathology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"Mehta P.","year":"2020","unstructured":"Mehta P.; McAuley D.F.; Brown M.; Sanchez E.; Tattersall R.S.; Manson J.J.; COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020,395(10229),1033-1034","journal-title":"Lancet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"45100707","DOI":"10.1016\/j.blre.2020.100707","author":"England J.T.","year":"2021","unstructured":"England J.T.; Abdulla A.; Biggs C.M.; Weathering the COVID-19 storm: Lessons from hematologic cytokine syn-dromes. Blood Rev 2021,45100707","journal-title":"Blood Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"Chen G.","year":"2020","unstructured":"Chen G.; Wu D.; Guo W.; Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020,130(5),2620-2629","journal-title":"J Clin Invest"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1515\/cclm-2020-0369","volume":"58","author":"Henry B.M.","year":"2020","unstructured":"Henry B.M.; de Oliveira M.H.S.; Benoit S.; Plebani M.; Lippi G.; Hematologic, biochemical and immune biomarker abnormali-ties associated with severe illness and mortality in corona-virus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med 2020,58(7),1021-1028","journal-title":"Clin Chem Lab Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"Netea M.G.","year":"2020","unstructured":"Netea M.G.; Rovina N.; Koulouris N.; Clinical and translational report complex immune dysregulation in COVID\u201019 patients with severe respiratory failure II clinical and translational re-port complex immune dysregulation in COVID\u201019 patients with severe respiratory failure. Cell Host Microbe 2020,27(6),992-1000","journal-title":"Cell Host Microbe"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.carrev.2021.03.023","volume":"35","author":"Cornelissen A.","year":"2022","unstructured":"Cornelissen A.; Kutyna M.; Cheng Q.; Effects of simulat-ed COVID-19 cytokine storm on stent thrombogenicity. Cardiovasc Revasc Med 2022,35,129-138","journal-title":"Cardiovasc Revasc Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc2013656","volume":"383","author":"Bowles L.","year":"2020","unstructured":"Bowles L.; Platton S.; Yartey N.; Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med 2020,383(3),288-290","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.thromres.2014.03.014","volume":"133","author":"Lupu F.","year":"2014","unstructured":"Lupu F.; Keshari R.S.; Lambris J.D.; Coggeshall K.M.; Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 2014,133(Suppl. 1),S28-S31","journal-title":"Thromb Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","volume":"220","author":"Magro C.","year":"2020","unstructured":"Magro C.; Mulvey J.J.; Berlin D.; Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020,220,1-13","journal-title":"Transl Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"Crayne C.B.","year":"2019","unstructured":"Crayne C.B.; Albeituni S.; Nichols K.E.; Cron R.Q.; The immu-nology of macrophage activation syndrome. Front Immunol 2019,10,119","journal-title":"Front Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2020.06.063","volume":"131","author":"Hamadeh A.","year":"2020","unstructured":"Hamadeh A.; Aldujeli A.; Briedis K.; Characteristics and outcomes in patients presenting with COVID-19 and ST-segment elevation myocardial infarction. Am J Cardiol 2020,131,1-6","journal-title":"Am J Cardiol"},{"key":"ref=38","first-page":"308","volume":"9","author":"Kariyanna P.T.","year":"2021","unstructured":"Kariyanna P.T.; Jayarangaiah A.; Das S.; COVID-19 and coronary stent thrombosis: A systematic review of literature. Am J Med Case Rep 2021,9(6),308-311","journal-title":"Am J Med Case Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e006631","DOI":"10.1161\/CIRCOUTCOMES.120.006631","volume":"13","author":"Tam C.F.","year":"2020","unstructured":"Tam C.F.; Cheung K.S.; Lam S.; Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes 2020,13(4),e006631","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jacc.2020.07.022","volume":"76","author":"Choudry F.A.","year":"2020","unstructured":"Choudry F.A.; Hamshere S.M.; Rathod K.S.; High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2020,76(10),1168-1176","journal-title":"J Am Coll Cardiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/09537104.2021.1936478","volume":"32","author":"Violi F.","year":"2021","unstructured":"Violi F.; Cammisotto V.; Pignatelli P.; Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. Platelets 2021,32(8),1009-1017","journal-title":"Platelets"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"E482","DOI":"10.1016\/S0735-1097(12)60483-5","volume":"59","author":"Storey R.F.","year":"2012","unstructured":"Storey R.F.; Steg P.; James S.; Reduction in pulmonary adverse events and associated sepsis and mortality in acute coronary syndrome patients treated with ticagrelor compared to clopidogrel: A post hoc analysis of the Plato study. J Am Coll Cardiol 2012,59(13S),E482","journal-title":"J Am Coll Cardiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/ijms21041391","volume":"21","author":"Mansour A.","year":"2020","unstructured":"Mansour A.; Bachelot-Loza C.; Nesseler N.; Gaussem P.; Gouin-Thibault I.; P2Y12 inhibition beyond thrombosis: Ef-fects on inflammation. Int J Mol Sci 2020,21(4),1391","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/path.4935","volume":"243","author":"Chrysanthopoulou A.","year":"2017","unstructured":"Chrysanthopoulou A.; Kambas K.; Stakos D.; Interferon lambda1\/IL-29 and inorganic polyphosphate are novel regula-tors of neutrophil-driven thromboinflammation. J Pathol 2017,243(1),111-122","journal-title":"J Pathol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"216108468","DOI":"10.1016\/j.clim.2020.108468","author":"Omarjee L.","year":"2020","unstructured":"Omarjee L.; Meilhac O.; Perrot F.; Janin A.; Mahe G.; Can Ti-cagrelor be used to prevent sepsis-induced coagulopathy in COVID-19? Clin Immunol 2020,216108468","journal-title":"Clin Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.3390\/ijms21103625","volume":"21","author":"Mitsios A.","year":"2020","unstructured":"Mitsios A.; Chrysanthopoulou A.; Arampatzioglou A.; Ticagrelor exerts immune-modulatory effect by attenuating neutrophil extracellular traps. Int J Mol Sci 2020,21(10),3625","journal-title":"Int J Mol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","volume":"63","author":"Cattaneo M.","year":"2014","unstructured":"Cattaneo M.; Schulz R.; Nylander S.; Adenosine-mediated ef-fects of ticagrelor: Evidence and potential clinical relevance. J Am Coll Cardiol 2014,63(23),2503-2509","journal-title":"J Am Coll Cardiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s43440-021-00309-0","volume":"73","author":"Akkaif M.A.","year":"2021","unstructured":"Akkaif M.A.; Ng M.L.; Sk Abdul Kader M.A.; Daud N.A.A.; Sha\u2019aban A.; Ibrahim B.; A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacol Rep 2021,73(6),1551-1564","journal-title":"Pharmacol Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2013.00085","volume":"4","author":"Hask&#xF3; G.","year":"2013","unstructured":"Hask&#xF3; G.; Cronstein B.; Regulation of inflammation by adeno-sine. Front Immunol 2013,4,85","journal-title":"Front Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/SHK.0000000000000745","volume":"47","author":"Panka B.A.","year":"2017","unstructured":"Panka B.A.; de Grooth H.J.; Spoelstra-de Man A.M.; Looney M.R.; Tuinman P.R.; Prevention or treatment of ARDS with aspirin: A review of preclinical models and meta-analysis of clinical studies. Shock 2017,47(1),13-21","journal-title":"Shock"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/heartjnl-2014-306685","volume":"101","author":"Loeffen R.","year":"2015","unstructured":"Loeffen R.; Godschalk T.C.; van Oerle R.; The hypercoag-ulable profile of patients with stent thrombosis. Heart 2015,101(14),1126-1132","journal-title":"Heart"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbrc.2007.05.092","volume":"359","author":"Du L.","year":"2007","unstructured":"Du L.; Kao R.Y.; Zhou Y.; Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun 2007,359(1),174-179","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1055\/s-0040-1718415","volume":"4","author":"Frydman G.H.","year":"2020","unstructured":"Frydman G.H.; Streiff M.B.; Connors J.M.; Piazza G.; The poten-tial role of coagulation factor Xa in the pathophysiology of COVID-19: A role for anticoagulants as multimodal therapeu-tic agents. TH Open 2020,4(4),e288-e299","journal-title":"TH Open"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","volume":"359","author":"D&#xF6;rffler-Melly J.","year":"2002","unstructured":"D&#xF6;rffler-Melly J.; de Jonge E.; Pont A.C.; Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002,359(9309),849-850","journal-title":"Lancet"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jdmv.2020.03.002","volume":"45","year":"2020","unstructured":"Bal dit Sollier C, Dillinger JG, Drouet L. dit Sollier CB, Dil-linger JG, Drouet L. Anticoagulant activity and pleiotropic ef-fects of heparin. J Med Vasc 2020,45(3),147-157","journal-title":"J Med Vasc"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1684\/stv.2013.0807","volume":"25","year":"2013","unstructured":"Bal dit Sollier C, Drouet L. dit Sollier CB, Drouet L. Non anticoagulant properties of heparin preparations: Practical considerations. STV Sang Thromb Vaiss 2013,25(6),389-398","journal-title":"STV Sang Thromb Vaiss"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0002-9149(03)00105-X","volume":"91","author":"Montalescot G.","year":"2003","unstructured":"Montalescot G.; Bal-dit-Sollier C.; Chibedi D.; Compari-son of effects on markers of blood cell activation of enoxapa-rin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 2003,91(8),925-930","journal-title":"Am J Cardiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"C97","DOI":"10.1152\/ajpcell.00009.2010","volume":"299","author":"Rao N.V.","year":"2010","unstructured":"Rao N.V.; Argyle B.; Xu X.; Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 2010,299(1),C97-C110","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=59","volume":"32","author":"Grouve E","year":"2007","unstructured":"Grouve E; Kristensen S.; Stent thrombosis: Definitions, mechanisms and prevention. E-J Cardiol Pract 2007,32(5)","journal-title":"E-J Cardiol Pract"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.carrev.2019.04.016","volume":"21","author":"Ndunda P.","year":"2020","unstructured":"Ndunda P.; Vindhyal M.R.; Muutu T.; Fanari Z.; Clinical out-comes of the dual-therapy CD34 antibody-covered sirolimus-eluting stent versus standard drug-eluting coronary stents: A Meta-Analysis. Cardiovascular Revascularization Medicine 2020,21(2),213-221","journal-title":"Cardiovascular Revascularization Medicine"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.thromres.2014.05.006","volume":"134","author":"Stimpfle F.","year":"2014","unstructured":"Stimpfle F.; Karathanos A.; Droppa M.; Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thromb Res 2014,134(1),105-110","journal-title":"Thromb Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/heartjnl-2011-301164","volume":"98","author":"Sambu N.","year":"2012","unstructured":"Sambu N.; Radhakrishnan A.; Dent H.; Personalised an-tiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) regis-try. Heart 2012,98(9),706-711","journal-title":"Heart"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1002\/ccd.28948","volume":"97","author":"Lacour T.","year":"2021","unstructured":"Lacour T.; Semaan C.; Genet T.; Ivanes F.; Insights for in-creased risk of failed fibrinolytic therapy and stent throm-bosis associated with COVID-19 in ST-segment elevation myocardial infarction patients. Catheter Cardiovasc Interv 2021,97(2),E241-E243","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e10708","DOI":"10.7759\/cureus.10708","volume":"12","author":"Zaher N.","year":"2020","unstructured":"Zaher N.; Sattar Y.; Mahmood S.; Vacek T.; Alraies M.C.; COVID-19 infection complicated by a complete occlusion of the left circumflex artery with acute restenosis after drug-eluting stent placement. Cureus 2020,12(9),e10708","journal-title":"Cureus"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4070\/kcj.2020.0166","volume":"50","author":"Galeazzi G.L.","year":"2020","unstructured":"Galeazzi G.L.; Loffi M.; Di Tano G.; Danzi G.B.; Severe COVID-19 pneumonia and very late stent thrombosis: A trigger or in-nocent bystander? Korean Circ J 2020,50(7),632-633","journal-title":"Korean Circ J"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/08998280.2020.1812792","volume":"34","author":"Ayan M.","year":"2021","unstructured":"Ayan M.; Kovelamudi S.; Al-Hawwas M.; Subacute stent thrombosis in a patient with COVID-19 pneumonia. Baylor University Medical Center Proceedings Taylor  2021,34(1),175-7","journal-title":"Baylor University Medical Center Proceedings Taylor"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamacardio.2020.2459","volume":"5","author":"Antu&#xF1;a P.","year":"2020","unstructured":"Antu&#xF1;a P.; Rivero F.; Del Val D.; Cuesta J.; Alfonso F.; Late coronary stent thrombosis in a patient with coronavirus dis-ease 2019. JAMA Cardiol 2020,5(10),1195-1198","journal-title":"JAMA Cardiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00392-020-01663-4","volume":"110","author":"Hinterseer M.","year":"2021","unstructured":"Hinterseer M.; Zens M.; Wimmer R.J.; Acute myocardial infarction due to coronary stent thrombosis in a symptomatic COVID-19 patient. Clin Res Cardiol 2021,110(2),302-306","journal-title":"Clin Res Cardiol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"898","DOI":"10.21037\/cdt-20-485","volume":"10","author":"Choudhary R.","year":"2020","unstructured":"Choudhary R.; Kaushik A.; Sharma J.B.; COVID-19 pandemic and stent thrombosis in a post percutaneous coronary inter-vention patient-a case report highlighting the selection of P2Y12 inhibitor. Cardiovasc Diagn Ther 2020,10(4),898-901","journal-title":"Cardiovasc Diagn Ther"}],"container-title":["Current Cardiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573403X18666220512142019","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204669\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573403X18666220512142019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T12:59:50Z","timestamp":1677848390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204669\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573403x18666220512142019","relation":{},"ISSN":["1573-403X"],"issn-type":[{"value":"1573-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e120522204669"}}